48 results
8-K
EX-99.2
ALDX
Aldeyra Therapeutics Inc
25 Apr 24
Regulation FD Disclosure
7:01am
, but not limited to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: the goals
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
25 Apr 24
Regulation FD Disclosure
7:01am
: the goals, opportunity, and potential forreproxalap, ADX - 2191, ADX - 246, ADX - 248, and ADX - 629; anticipated clinical or regulatory milestones
8-K
ALDX
Aldeyra Therapeutics Inc
25 Apr 24
Regulation FD Disclosure
7:01am
to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity
8-K
EX-99.1
2xxidq96lwo5z9
28 Mar 24
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
7:01am
8-K
EX-99.1
6volrxk2atqhxwawjexx
13 Feb 24
Regulation FD Disclosure
4:00pm
8-K
EX-99.1
3ly38anin4una60kxm
4 Jan 24
Other Events
7:00am
8-K
EX-99.1
c2k1kxdm 4hfs
19 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.2
8ftz3 owgmh
19 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
6cr3ro
28 Nov 23
Regulation FD Disclosure
7:16am
8-K
EX-99.1
f04fp7 vw16g51jrxb0d
29 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.2
itftcmabdacoma8
29 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
vgjtaqowpc9o1 cl
27 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.2
n1man46ay s6tztp2wo1
27 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
218ltimk
15 Jun 23
Regulation FD Disclosure
7:01am